Heya Everyone! Wow, just found out moments ago that one of my most sought after dreams has been fulfilled. I am published as a renowned Biofield Energy Healer in the American Journal of Bioscience! I cannot believe it!!
It has been a six year process, but I am finally published in a very prestigious scientific journal as a Biofield Energy Healer. I am not even going to try to be humble about this as it is almost impossible even for a typical university scientist to get published in a journal like this. And the hoops that have been jumped to do this. I can’t begin to tell you!! I am extremely grateful to all the other scientists and Biofield Healers that helped to make this happen. There is no way that this could have been done without all of these amazing individuals. Below, you will be able to read the abstracts for the two studies. You probably don’t want to try to understand every word, but do read the last sentence of each abstract. There will be at least 8 projects that will be submitted and probably accepted in the near future. You can look up the complete journal write up and citations by googling the American Journal of BioScience – November, 2016. The conclusions are astounding!! Many love and light blessings, Elizabeth
Effect of Biofield Energy Healing Based Herbomineral Formulation on Pro-inflammmatory Cytokines Expression in Biofield Treated Mouse Splenocyte Cells: Impact of the Trivedi Effect.
DISCLAIMER – Please note that my energy healing abilities have been tested and validated via preclinical cell-based and mouse-model experiments. I have not done any clinical trial that suggests any kind of results or benefits related to human health. No human health-related benefits have been scientifically validated, and I do not give any guarantee to provide any kind of health benefits.
Abstract: A proprietary herbomineral formulation was formulated with four ingredients; a mixture of the minerals (zinc, magnesium, and selenium) and the herbal root extract ashwagandha. The aim of the study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect® ) on the herbomineral formulation in splenocyte cells, which were isolated from Biofield Treated mice. The test formulation was divided into two parts. One part was denoted as the control without any Biofield Energy Treatment, while the other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Healing Treatment remotely from seven renowned Biofield Energy Healers. The splenocyte cells were treated with the test formulation at concentrations ranges from 0.00001053 to 10.53 μg/mL and analyzed after 48 hours of treatment by MTT assay. The cell viability data showed safe concentrations up to 1.053 μg/mL with viability ranges from 69.22% to 123.88% in the test formulation groups. The expression of TNF-α was decreased by 4.82% at 1.053 μg/mL in the Biofield Energy Treated test formulation compared with the vehicle control. The level of TNF-α was significantly decreased by 2.02%, 4.92%, and 18.78% at 0.00001053, 0.001053, and 1.053 μg/mL, respectively in the Biofield Energy Treated test formulation group as compared to the untreated test formulation. The expression of IL-1β was significantly reduced by 83.65%, 92.15%, 27.30%, and 41.88% at 0.00001053, 0.0001053, 0.001053, and 1.053 μg/mL, respectively in the Biofield Energy Treated test formulation compared with the vehicle control. The Biofield Treated test formulation showed significant reduction of IL-1β by 17.26%, 92.61% (p≤0.001), 34.62% (p≤0.05), and 16.13% at 0.00001053, 0.0001053, 0.001053, and 1.053 μg/mL, respectively compared with the untreated test formulation. Additionally, the expression of chemokine MIP-1α was significantly reduced by 17.03%, 10.99%, 22.33%, 24.21%, 21.61%, and 30.67% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, and 1.053 μg/mL, respectively in the Biofield Treated test formulation compared with the vehicle control. The MIP-1α expression was significantly reduced by 19.32% and 12.56% at 0.01053 and 0.1053 μg/mL, respectively in the Biofield Treated test formulation compared with the untreated test formulation. The overall results demonstrated that the Biofield Energy Treated test formulation significantly down-regulated the expression of TNF-α, IL- 1β, and MIP-1α in the Biofield Treated mice splenocyte cells compared to the untreated test formulation. These data suggest that the Biofield Treated test formulation can be used for autoimmune and inflammatory diseases, stress management and anti-aging by improving overall health.
Evaluation of Pro-Inflammatory Cytokines Expression in Mouse Splenocyte Cells After Incubation with the Biofield Energy Healing Based Herbomineral Formulations and Influece of the Trivedi Effect.
Abstract: The use of herbomineral formulations in the healthcare sector has increased due to their high safety and better therapeutic action. A new proprietary herbomineral formulation was formulated with a combination of the herbal root extract ashwagandha and minerals viz. zinc, magnesium, and selenium. The aim of the study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect® ) on the test formulation in splenocytes. The test formulation was divided into two parts; one was the control without the Biofield Energy Treatment, while the other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Healing Treatment remotely by seven renowned Biofield Energy Healers. The MTT assay showed that the test formulation exhibited safe concentrations up to 1.053 μg/mL with cell viability ranging from 88.19% to 110.30% in the Biofield Energy Treated sample. The Biofield Energy Healing significantly enhanced the cell viability as compared with the untreated test formulation. The expression of TNF-α was significantly inhibited by 7.23% at 1.053 μg/mL in the Biofield Energy Treated test formulation compared with the vehicle control. The level of TNF-α was significantly decreased by 3.90%, 11.74%, 3.12%, and 9.17% at 0.001053, 0.01053, 0.1053 and 1.053 μg/mL, respectively in the Biofield Energy Treated test formulation compared with the untreated test formulation. Additionally, the expression of IL-1β was significantly reduced by 28.98%, 51.23%, 53.06%, 48.98%, 55.71%, and 59.10% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, and 1.053 μg/mL, respectively in the Biofield Energy Treated test formulation compared with the vehicle control. Further, the Biofield Treated test formulation showed significant reduction of IL-1β by 35.07% (p≤0.05), 47.46% (p≤0.05), and 57.51% (p≤0.01) at 0.001053, 0.1053, and 1.053 μg/mL, respectively compared with the untreated test formulation. Similarly, the MIP-1α expression was inhibited by the Biofield Energy Treated formulation and showed immunosuppressive activity at 0.00001053, 0.0001053, 0.001053, and 0.01053 μg/mL by 19.38%, 24.97%, 31.23%, and 25.41%, respectively compared with the vehicle control group. The Biofield Treated test formulation significantly (p<0.001) reduced the MIP-1α expression by 19.33%, 22.57%, and 30.50% at 0.0001053, 0.001053, and 0.01053 μg/mL, respectively compared with the untreated test formulation. Overall, The Trivedi Effect® – Biofield Energy Healing (TEBEH) significantly down-regulated the pro-
inflammatory cytokines and potentiated the immunosuppressive effect of the Biofield Energy Treated test formulation, which can be better utilized for organ transplants, autoim.